Results of an Interim Safety Analysis of a Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) in Previously Untreated and Relapsed Pa... von Yimer, Habte, Melear, Jason, Faber, Edward, Bensinger, William I., Burke, John M, Gunawardena, Sriya, Sean, Murphy, Parros, Hollee, Lutska, Yana, Darif, Mohamed, Londhe, Anil, Qi, Ming, Ukropec, Jon, Lin, Thomas, Rifkin, Robert M.

Volltext

Results of an Early Access Treatment Protocol (EAP) of Daratumumab in United States Patients with Relapsed or Refractory Multiple Myeloma von Chari, Ajai, Mark, Tomer M, Krishnan, Amrita, Stockerl-Goldstein, Keith, Usmani, Saad Z, Londhe, Anil, Etheredge, Delores, Parros, Hollee, Fleming, Sarah, Liu, Baolian, Freeman, Scott, Ukropec, Jon, Lin, Thomas, Lonial, Sagar

Volltext

Use of Montelukast to Reduce Infusion Reactions in an Early Access Treatment Protocol of Daratumumab in United States Patients with Relapsed or Refractory Multiple Myeloma von Chari, Ajai, Mark, Tomer M, Krishnan, Amrita, Stockerl-Goldstein, Keith, Usmani, Saad Z, Londhe, Anil, Etheredge, Delores, Parros, Hollee, Fleming, Sarah, Liu, Baolian, Freeman, Scott, Ukropec, Jon, Lin, Thomas, Nooka, Ajay K

Volltext